Capecitabine (Xeloda; F. Hoffmann--La Roche, Basel, Switzerland) is an oral fluoropyrimidine with similar efficacy to bolus 5-fluorouracil/folinic acid (5-FU/FA) in the first-line treatment of metastatic colorectal cancer ([@bib12]; [@bib18]) and as adjuvant therapy for stage III colon cancer ([@bib17]). The efficacy of capecitabine and a 3-weekly dose of oxaliplatin (XELOX regimen) is also non-inferior to 5-FU/FA plus oxaliplatin (FOLFOX4 or FOLFOX6) in the first- and second-line treatment of patients with metastatic colorectal cancer ([@bib14]; [@bib2]; [@bib10]).

The largest of the recent trials evaluating XELOX, NO16966 (XELOX-1), started as a two-arm, randomised, non-inferiority, phase III study designed to compare XELOX with FOLFOX4 as first-line treatment for metastatic colorectal cancer. The protocol was subsequently amended to include the further addition of bevacizumab or placebo using a 2 × 2 factorial design. The study had two co-primary objectives: (1) to evaluate the non-inferiority of XELOX ± bevacizumab *vs* FOLFOX4 ± bevacizumab; and (2) to evaluate the superiority of bevacizumab *vs* placebo when combined with oxaliplatin-based chemotherapy (i.e., XELOX or FOLFOX4). The results pertaining to both objectives have been previously published ([@bib15]; [@bib2]). The present paper describes an updated analysis of overall survival (OS) for the comparison of XELOX/XELOX-placebo/XELOX-bevacizumab *vs* FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab from study NO16966.

Patients and methods
====================

The methods of this trial have been described in detail previously ([@bib15]; [@bib2]). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from all patients participating in the study. Approval of the protocol was obtained from an independent ethics committee or institutional review board of each site.

Patient population
------------------

Patients ⩾18 years of age with histologically confirmed, unresectable metastatic colorectal cancer (⩾1 unidimensionally measurable lesion), an ECOG performance status of ⩽1 and a life expectancy of \>3 months were eligible. No previous systemic therapy for metastatic disease or previous oxaliplatin or bevacizumab were allowed. Patients were required to have adequate haematologic/clotting, hepatic and renal function. Patients were excluded if they had any of the following: clinically significant cardiovascular disease; clinically detectable ascites; use of full-dose anticoagulants or thrombolytics; known CNS metastases; serious non-healing wound, ulcer or bone fracture; known bleeding diathesis or coagulopathy; and proteinuria ⩾500 mg per 24 h.

Treatment plan
--------------

Patients were randomly assigned to treatment using an interactive voice response system. Randomisation was stratified by region, ECOG performance status, liver as a metastatic site, number of metastatic sites (organs) and alkaline phosphatase level.

XELOX consisted of a 2-h intravenous infusion of oxaliplatin 130 mg m^--2^ on day 1 plus oral capecitabine 1000 mg m^--2^ twice daily for 2 weeks as a 3-week cycle. The first dose of capecitabine was given in the evening of day 1 and the last dose on the morning of day 15. The FOLFOX4 regimen has been previously described ([@bib7]). After amendment of the study protocol, bevacizumab (7.5 mg kg^--1^ every third week) or placebo was added to XELOX, and bevacizumab (5 mg kg^--1^ every second week) or placebo to FOLFOX4. Bevacizumab or placebo was given as a 30- to 90-min intravenous infusion on day 1 of each cycle before oxaliplatin.

Treatment was continued until disease progression or for 48 weeks, whichever came first (study treatment phase). Patients who completed the 48-week treatment phase without disease progression were eligible to continue treatment until progression (post-study treatment phase). Patients whose tumour became operable, and for whom resection was performed, were allowed to enter the post-study treatment phase.

Assessments
-----------

Tumour assessments (CT scan, MRI) were performed within 28 days before starting study treatment and repeated after every two XELOX cycles and every three FOLFOX4 cycles (i.e., every sixth week in both arms), and at the end of treatment. After completion of study treatment, patients were followed every 3 months until disease progression and/or death.

Patients were evaluated for adverse events during therapy and until 28 days after the last study drug dose. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 3. Predefined adverse events of special interest for chemotherapy were: grade 3/4 neutropenia/granulocytopenia; grade 3/4 neurosensory toxicity; grade 3/4 diarrhoea; grade 3/4 vomiting/nausea; grade 3/4 stomatitis and grade 3 hand-foot syndrome.

Statistical analysis
--------------------

The intent-to-treat (ITT) patient population included all patients who underwent randomisation and signed the informed consent form. The eligible patient population (EPP) was the ITT population minus patients who did not receive at least one dose of study drug, and those patients who violated major protocol inclusion/exclusion criteria. As the results for the EPP population were the same as for the ITT population, ITT data only will be presented in this paper. The safety population included all patients receiving at least one dose of study drug.

Overall survival was defined as the time from the date of randomisation to the date of death. Patients who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. Overall survival was analysed using a Cox model and presented as Kaplan--Meier estimates with hazard ratios (HRs) and 97.5% confidence intervals (CIs).

The primary analysis of NO16966 was event driven and was performed on 31 January 2006 when 1200 progression-free survival events had occurred in the EPP; this approach ensured 90% power at an *α* level of 2.5 ([@bib15]). A further planned follow-up analysis of OS was performed at the time of the 4-month safety update.

As the study was not powered for formal testing of non-inferiority for OS, the OS analysis is exploratory and the results described by Kaplan--Meier estimates with HRs and 97.5% CIs. An additional exploratory analysis of OS was performed to control for any possible crossover effects of FOLFOX in patients who received XELOX as their first-line regimen. In this analysis, patients in the XELOX arms who received FOLFOX4 or similar regimen as second-line therapy were censored.

Results
=======

Patient population
------------------

Between July 2003 and May 2004, 634 patients were randomised in the two-arm portion of the study. Between February 2004 and February 2005, a further 1400 patients were randomised in the 2 × 2 factorial part of the study. Overall, 2034 patients made up the ITT population ([Figure 1](#fig1){ref-type="fig"}). The baseline demographic and clinical characteristics were well balanced between treatment arms ([Table 1](#tbl1){ref-type="table"}).

Treatment exposure and second-line therapy
------------------------------------------

The median dose intensities (ratio of dose received to dose planned) of 5-FU, capecitabine, oxaliplatin and bevacizumab were ⩾0.89 in all treatment arms. The median number of cycles administered was 11 (range 1--24) in the FOLFOX4/FOLFOX4-placebo group, 12 (range 1--25) in the FOLFOX4-bevacizumab group, 7 (range 1--18) in the XELOX/XELOX-placebo group and 8 (range 1--17) in the XELOX-bevacizumab group.

There were no major imbalances between the treatment groups with respect to the use of second-line therapy: XELOX-containing arms (65%) and FOLFOX4-containing arms (70%). The agents most commonly used were: irinotecan (56% with FOLFOX4 *vs* 53% with XELOX); 5-FU (41 *vs* 34%); capecitabine (19 *vs* 14%); cetuximab (20 *vs* 18%); and bevacizumab (10 *vs* 10%).

Overall survival
----------------

The OS data as at 31 July 2008 in the ITT population are shown in [Table 2](#tbl2){ref-type="table"}. The corresponding Kaplan--Meier curves for OS are shown in [Figure 2](#fig2){ref-type="fig"}.

For the whole NO16966 study population, median OS was 19.8 months in the pooled XELOX/XELOX-placebo/XELOX-bevacizumab arms *vs* 19.5 months in the pooled FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab arms, with a corresponding HR of 0.95 (97.5% CI 0.85--1.06).

In the pooled XELOX/XELOX-placebo arms, median OS was 19.0 *vs* 18.9 months in the pooled FOLFOX4/FOLFOX4-placebo arms, with a corresponding HR of 0.95 (97.5% CI 0.83--1.09).

In the XELOX-bevacizumab arm, median OS was 21.6 *vs* 21.0 months in the FOLFOX4-bevacizumab arm, with a corresponding HR of 0.95 (97.5% CI 0.78--1.15).

In the XELOX arm, median OS was 18.8 *vs* 17.7 months in the FOLFOX4 arm, with a corresponding HR of 0.87 (97.5% CI 0.72--1.05). FOLFOX4 or a similar regimen was given to 8% of patients in the pooled XELOX arms as second-line therapy (XELOX, *n*=15, XELOX-placebo, *n*=38, XELOX-bevacizumab, *n*=29). After censoring these patients, the median OS was 18.9 months in the pooled XELOX/XELOX-placebo arms and 18.9 months in the pooled FOLFOX4/FOLFOX4-placebo arms, with a corresponding HR of 0.94 (97.5% CI 0.82--1.08), and 21.6 months in the XELOX-bevacizumab arm and 21.0 months in the FOLFOX4-bevacizumab arm (HR=0.93; 97.5% CI 0.76--1.13).

Safety
------

For the updated safety assessment of XELOX *vs* FOLFOX4, patients in the pooled XELOX/XELOX-placebo (*n*=655) and pooled FOLFOX-4/FOLFOX4-placebo (*n*=648) arms were compared. The updated safety analysis showed that little had changed since the previous analysis ([@bib2]). Predefined adverse events of special interest and key events pooled by body system are presented in [Table 3](#tbl3){ref-type="table"}.

In general, XELOX and FOLFOX4 had a similar profile of adverse events. The most common adverse events were gastrointestinal (i.e., diarrhoea, nausea, vomiting and stomatitis) and neurosensory toxicities (i.e., paraesthesia and peripheral neuropathy). However, there were differences between the two regimens in the rates at which key events occurred. FOLFOX4/FOLFOX4-placebo was associated with more grade 3/4 neutropenia/granulocytopenia (44%) and febrile neutropenia (5%) than XELOX/XELOX-placebo (7 and \<1%, respectively). Conversely, XELOX/XELOX-placebo was associated with more hand-foot syndrome (all-grade, 31 *vs* 11% grade 3, 6 *vs* 1%) and diarrhoea (all-grade, 66 *vs* 61% grade 3/4, 20 *vs* 11%) than FOLFOX4/FOLFOX4-placebo, although the rate of grade 4 diarrhoea was 1% with both regimens. Rates of grade 3/4 neurosensory toxicity were similar with both regimens (17%). Cardiac disorders were reported in 6 (1%) XELOX/XELOX-placebo recipients and 9 (1%) FOLFOX-4/FOLFOX4-placebo recipients. The addition of bevacizumab did not alter the similarities and differences in safety profiles between XELOX and FOLFOX4 ([Table 4](#tbl4){ref-type="table"}).

Treatment-related mortality up to 28 days after the last treatment dose was documented in 11 (1.7%) FOLFOX4/FOLFOX4-placebo patients and in 15 (2.3%) XELOX/XELOX-placebo patients. The respective 60-day all-cause mortality rates were 2.3% (*n*=15) and 3.4% (*n*=22).

Discussion
==========

The primary efficacy analysis of study NO16966 showed that XELOX is non-inferior to FOLFOX4 in terms of progression-free survival, OS and overall response rate in the first-line treatment of patients with metastatic colorectal cancer ([@bib2]). This updated analysis of OS again demonstrates that XELOX and FOLFOX4 have similar efficacy and supports the primary efficacy findings. It is also notable that both XELOX and FOLFOX4 were similar in terms of OS after the addition of bevacizumab.

Overall survival is the most clinically meaningful and objective measure of efficacy in patients with cancer. However, potential differences between study treatments can be masked by second-line and later lines of chemotherapy when this end point is used ([@bib9]). In study NO16966, there were no restrictions regarding crossover or salvage therapies after the completion of study treatment. It is therefore possible that crossover to the alternate study treatment was a confounding factor in the present analysis. To allow for this, we performed a separate analysis in which all patients randomised to XELOX and who received FOLFOX as second-line therapy were censored. The results were consistent with those obtained in the ITT population and again support the similar efficacy of XELOX *vs* FOLFOX4.

The question of whether or not capecitabine is non-inferior to 5-FU/FA when given in combination with oxaliplatin in metastatic colorectal cancer has now been addressed in six different randomised phase III trials ([@bib8]; [@bib13]; [@bib14]; [@bib2]; [@bib5]; [@bib10]), of which NO16966 is the largest. The other five studies, which involved 300--600 patients each, were largely supportive of NO16966. In three of the studies, the efficacy of XELOX or OXXEL was shown to be similar to that of 5-FU/FA-oxaliplatin regimens ([@bib14]; [@bib5]; [@bib10]), whereas the remaining two were inconclusive with regard to non-inferiority ([@bib8]; [@bib13]). Since the completion of the phase III trials, three separate meta-analyses of relevant studies comparing capecitabine or 5-FU/FA plus oxaliplatin in patients with metastatic colorectal cancer have been performed ([@bib1]; [@bib3]; [@bib6]). Even though each meta-analysis included a different selection of phase II and III studies, the outcomes were very similar with respect to both progression-free survival (HR/relative risk 0.98--1.04) and OS (1.02--1.04). Thus, there is now strong evidence to support the non-inferiority of capecitabine when used in combination with oxaliplatin *vs* infusional 5-FU-based oxaliplatin regimens in the treatment of patients with metastatic colorectal cancer, both in the first- and second-line settings.

It is therefore likely that other considerations, such as tolerability profile, convenience, patient preference and cost, will assume greater importance when selecting the fluoropyrimidine backbone of a chemotherapy regimen. With regard to tolerability, both XELOX and FOLFOX have a similar profile of adverse events, but XELOX is associated with more grade 3 diarrhoea and hand-foot syndrome, whereas FOLFOX is associated with more grade 3/4 neutropenia and febrile neutropenia ([@bib14]; [@bib10]). This is supported by the updated safety data from NO16966 in the present paper.

In terms of convenience, XELOX requires fewer planned office visits than the FOLFOX regimens because oxaliplatin is administered every 3 weeks (rather than every 2 weeks) and because capecitabine is taken orally. This is supported by resource use data from NO16966, which showed that the need for drug administration visits, central venous access and patient travel and time were reduced with XELOX *vs* FOLFOX4 ([@bib16]). When costs were assigned to these data, the total direct costs of both regimens were similar, whereas the indirect costs of XELOX were considerably less than those of FOLFOX4 ([@bib11]). Similar observations were made in a cost comparison of capecitabine ± oxaliplatin *vs* 5-FU ± oxaliplatin based on a retrospective analysis of a US medical claims database ([@bib4]). Modified FOLFOX regimens, which involve a single 46- to 48-h infusion of 5-FU, are likely to be less costly than unmodified FOLFOX regimens ([@bib11]), although a complete assessment *vs* XELOX has yet to be performed.

In conclusion, updated survival data from study NO16966 show that XELOX is similar to FOLFOX4, confirming the primary analysis of progression-free survival. XELOX can be considered as a routine first-line treatment option for patients with metastatic colorectal cancer.
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###### Baseline patient characteristics (ITT population)

                                 **FOLFOX4 (*n*=317)**   **FOLFOX4- placebo (*n*=351)**   **FOLFOX4- bevacizumab (*n*=349)**   **XELOX (*n*=317)**   **XELOX- placebo (*n*=350)**   **XELOX- bevacizumab (*n*=350)**                                   
  ------------------------------ ----------------------- -------------------------------- ------------------------------------ --------------------- ------------------------------ ---------------------------------- ----- ------ ----- ------ ----- ------
  *Gender*                                                                                                                                                                                                                                             
   Male                          204                     64                               186                                  53                    205                            59                                 194   61     205   59     213   61
   Female                        113                     36                               165                                  47                    144                            41                                 123   39     145   41     137   39
                                                                                                                                                                                                                                                        
  *Age, years*                                                                                                                                                                                                                                         
   Median                        62                      60                               60                                   61                    61                             61                                                                 
   Range                         24--83                  26--83                           19--82                               24--84                18--83                         18--86                                                             
                                                                                                                                                                                                                                                        
  *ECOG performance status*                                                                                                                                                                                                                            
   0                             163                     51                               211                                  60                    198                            57                                 160   50     207   59     207   59
   1                             154                     49                               138                                  40                    147                            43                                 157   50     143   41     142   41
   2                             0                       0                                0                                    0                     0                              0                                  0     0      0     0      1     \<1
                                                                                                                                                                                                                                                        
  *Primary tumour site*                                                                                                                                                                                                                                
   Colorectal                    17                      5                                25                                   7                     28                             8                                  30    9      30    9      32    9
   Colon                         200                     63                               232                                  66                    223                            64                                 204   64     233   67     236   67
   Rectal                        100                     32                               94                                   27                    98                             28                                 83    26     87    25     82    23
                                                                                                                                                                                                                                                        
  *Stage at first diagnosis*                                                                                                                                                                                                                           
   Local regional                144                     45                               141                                  40                    128                            37                                 133   42     138   39     122   35
   Metastatic                    173                     55                               210                                  60                    221                            63                                 184   58     212   61     228   65
                                                                                                                                                                                                                                                        
  *Number of metastatic sites*                                                                                                                                                                                                                         
   0                             1                       0.3                              1                                    0.3                   1                              0.3                                0     0      0     0      0     0
   1                             118                     37.2                             142                                  40.5                  150                            43.0                               127   40.1   155   44.3   134   38.3
   2                             121                     38.2                             122                                  34.8                  132                            37.8                               106   33.4   112   32.0   121   34.6
   3                             47                      14.8                             65                                   18.5                  44                             12.6                               55    17.4   58    16.6   64    18.3
   ⩾4                            30                      9.5                              21                                   6.0                   22                             6.3                                29    9.1    25    7.1    31    8.9
                                                                                                                                                                                                                                                        
  *Alkaline phosphatase*                                                                                                                                                                                                                               
   Abnormal                      135                     43                               147                                  42                    146                            42                                 132   42     149   43     156   45
   Normal                        182                     57                               201                                  58                    199                            58                                 183   58     200   57     191   55
                                                                                                                                                                                                                                                        
  *Previous adjuvant therapy*                                                                                                                                                                                                                          
   No                            234                     74                               266                                  76                    261                            75                                 229   72     259   74     274   78
   Yes                           83                      26                               85                                   24                    88                             25                                 88    28     91    26     76    22

Abbreviations: ITT=intent-to-treat; ECOG=Eastern Cooperative Oncology Group; FOLFOX4=infused fluorouracil, folinic acid and oxaliplatin; XELOX=capecitabine and oxaliplatin.

###### Overall survival by treatment subgroup (ITT population)

  **Treatment subgroup comparison**              **No. of events**  **Median time to event (months)**   **Hazard ratio (97.5% CI)**
  --------------------------------------------- ------------------- ----------------------------------- -----------------------------
  FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab           847         19.5                                0.95 (0.85--1.06)
  XELOX/XELOX-placebo/XELOX-bevacizumab                 820         19.8                                 
  FOLFOX4/FOLFOX4-placebo                               573         18.9                                0.95 (0.83--1.09)
  XELOX/XELOX-placebo                                   546         19.0                                 
  FOLFOX4-bevacizumab                                   274         21.0                                0.95 (0.78--1.15)
  XELOX-bevacizumab                                     274         21.6                                 
  FOLFOX4                                               284         17.7                                0.87 (0.72--1.05)
  XELOX                                                 266         18.8                                 

Abbreviations: ITT=intent-to-treat; CI=confidence interval; FOLFOX4=infused fluorouracil, folinic acid and oxaliplatin; XELOX=capecitabine and oxaliplatin.

###### Adverse events of special interest to chemotherapy and key events pooled by body system (treatment-related and unrelated)

                                                      **FOLFOX4/FOLFOX4-placebo (*n*=648)**   **XELOX/ XELOX-placebo (*n*=655)**                                                                                                             
  --------------------------------------------------- --------------------------------------- ------------------------------------ ------------------------------ ------------------------------ ----- ----- ------------------------------- ------------------------------
  All events                                          644                                     99                                   506                            78                             649   99    468                             72
                                                                                                                                                                                                                                              
  *Body system*                                                                                                                                                                                                                              
   Gastrointestinal disorders                         603                                     93                                   167                            26                             606   93    216                             33
   Blood/lymphatic disorders                          448                                     69                                   318                            49                             312   48    104                             16
   Infections/infestations                            292                                     45                                   66                             10                             210   32    45                              7
                                                                                                                                                                                                                                              
  *Events of special interest*                                                                                                                                                                                                               
   Neurosensory toxicity[a](#t3-fn2){ref-type="fn"}   515                                     80                                   107                            17                             534   82    114                             17
   Diarrhoea                                          394                                     61                                   74                             11                             429   66    133                             20
   Nausea/vomiting                                    452                                     70                                   47                             7                              464   71    52                              8
   Stomatitis                                         242                                     37                                   13                             2                              140   21    8                               1
   Neutropenia/granulocytopenia                       379                                     59                                   282                            44                             180   28    46                              7
   Febrile neutropenia                                ---                                     ---                                  31                             5                              ---   ---   6                               \<1
   Hand-foot syndrome                                 70                                      11                                   8[b](#t3-fn3){ref-type="fn"}   1[b](#t3-fn3){ref-type="fn"}   201   31    40[b](#t3-fn3){ref-type="fn"}   6[b](#t3-fn3){ref-type="fn"}

Abbreviations: FOLFOX4=infused 5-fluorouracil, folinic acid and oxaliplatin; XELOX=capecitabine and oxaliplatin.

Pooled term that includes burning sensation, dysaesthesia, hyper or hypoaesthesia, neuropathic pain, neuropathy, peripheral neuropathy, neurotoxicity, paraesthesia, peripheral (sensi)motor neuropathy, (chronic) polyneuropathy, sensory disturbance or loss, skin burning sensation, temperature intolerance, neuralgia, peroneal nerve palsy, autonomic neuropathy.

Grade 3 events only.

###### Adverse events of special interest to chemotherapy and key events pooled by body system (treatment-related and unrelated)

                                                      **FOLFOX4-bevacizumab (*n*=342)**   **XELOX-bevacizumab (*n*=353)**                                                                                                             
  --------------------------------------------------- ----------------------------------- --------------------------------- ------------------------------ ------------------------------ ----- ----- ------------------------------- -------------------------------
  All events                                          340                                 99                                289                            85                             351   99    266                             75
                                                                                                                                                                                                                                       
  *Body system*                                                                                                                                                                                                                       
   Gastrointestinal disorders                         320                                 94                                94                             28                             325   92    132                             37
   Blood/lymphatic disorders                          229                                 67                                159                            47                             125   35    44                              13
   Infections/infestations                            164                                 42                                31                             9                              137   39    21                              6
                                                                                                                                                                                                                                       
  *Events of special interest*                                                                                                                                                                                                        
   Neurosensory toxicity[a](#t4-fn2){ref-type="fn"}   281                                 82                                61                             18                             296   84    64                              18
   Diarrhoea                                          219                                 64                                44                             13                             224   64    77                              22
   Nausea/vomiting                                    235                                 69                                25                             7                              252   71    38                              11
   Stomatitis                                         141                                 41                                12                             4                              102   29    7                               2
   Neutropenia/granulocytopenia                       189                                 55                                138                            40                             70    20    25                              7
   Febrile neutropenia                                ---                                 ---                               15                             4                              ---   ---   4                               1
   Hand-foot syndrome                                 47                                  14                                6[b](#t4-fn3){ref-type="fn"}   2[b](#t4-fn3){ref-type="fn"}   141   40    42[b](#t4-fn3){ref-type="fn"}   12[b](#t4-fn3){ref-type="fn"}

Abbreviations: FOLFOX4=infused 5-fluorouracil, folinic acid and oxaliplatin; XELOX=capecitabine and oxaliplatin.

Pooled term that includes burning sensation, dysaesthesia, hyper or hypoaesthesia, neuropathic pain, neuropathy, peripheral neuropathy, neurotoxicity, paraesthesia, peripheral (sensi)motor neuropathy, (chronic) polyneuropathy, sensory disturbance or loss, skin burning sensation, temperature intolerance, neuralgia, peroneal nerve palsy, autonomic neuropathy.

Grade 3 events only.
